Research Triangle Park, N.C.-based Asensus Surgical, Inc. a medical device company that is digitizing the interface between the surgeon and patient to advance Performance-Guided Surgery, announces that it has received U.S. FDA 510(k) clearance for 5 mm diameter articulating instruments, adding to the Senhance Surgical System technology platform. Articulating instruments offer better access to difficult-to-reach areas of the anatomy by providing two additional degrees of freedom, company officials say.
“Bringing the benefits of 5 mm articulating instruments to the Senhance Surgical System in the U.S. will widen the clinical utility and value of our platform,” says Asensus Surgical President and CEO Anthony Fernando. “Combining articulation and haptics with augmented intelligence is a very promising development for performance-guided surgery.”
Asensus Surgical’s technology platform, the Senhance Surgical System, is a digital laparoscopic platform that leverages augmented intelligence to provide advanced performance through machine learning. Company officials say Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments.
Articulating instruments are the latest addition to the Senhance Surgical System in the United States, further enhancing surgical performance with robotic precision. These instruments have previously received the CE Mark for use in the European Union.
